Immune checkpoint inhibitors aiming to hinder the inhibitory interaction between PD-1 and its ligand PD-L1 have been developed, though high PD-L1 expression in the tumor cells did not correlate with poor prognosis of patients suffering from oral squamous cells carcinoma [37,38,39]. This evidence concerns the gene PDCD1 and oral cavity squamous cell carcinoma.